About Evgen Pharma PLC (LON:EVG)
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:EVG
- CUSIP: N/A
- Web: evgen.com/
Capitalization:- Market Cap: £13.74 million
- Outstanding Shares: 73,272,000
Average Prices:- 50 Day Moving Avg: GBX 17.51
- 200 Day Moving Avg: GBX 18.82
- 52 Week Range: GBX 15.25 - GBX 30.25
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.06 per share
- Price / Book: 3.13
Profitability:- EBITDA: ($3,640,000.00)
- Return on Equity: -56.78%
- Return on Assets: -52.02%
Misc:- Average Volume: 43,767 shs.
Frequently Asked Questions for Evgen Pharma PLC (LON:EVG)
What is Evgen Pharma PLC's stock symbol?
Evgen Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "EVG."
Where is Evgen Pharma PLC's stock going? Where will Evgen Pharma PLC's stock price be in 2017?
2 brokers have issued 12 month price objectives for Evgen Pharma PLC's stock. Their forecasts range from GBX 97 to GBX 97. On average, they anticipate Evgen Pharma PLC's stock price to reach GBX 97 in the next year. View Analyst Ratings for Evgen Pharma PLC.
Who are some of Evgen Pharma PLC's key competitors?
Some companies that are related to Evgen Pharma PLC include Xenetic Biosciences (XBIO), Midatech Pharma PLC (MTPH), Heat Biologics (HTBX), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX), Biopharmx Corp (BPMX), Cerulean Pharma (DARE), Anthera Pharmaceuticals (ANTH), Opexa Therapeutics (ACER), Kitov Pharmaceuticals Holdings (KTOV), Proteome Sciences plc (PRM), Bio Blast Pharma (ORPN), Ritter Pharmaceuticals (RTTR), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX), Biotie Therapies Corp (BITI) and Cynapsus Therapeutics (CYNA).
Who are Evgen Pharma PLC's key executives?
Evgen Pharma PLC's management team includes the folowing people:
- Barry Clare, Executive Chairman of the Board
- Stephen Joseph Franklin, Chief Executive Officer, Executive Director
- Richard Moulson, Chief Financial Officer, Director
- Hamina J. Patel, Chief Medical Officer
- Alan Barge, Non-Executive Director
- Marc F. D'Abbadie Ph.D., Non-Executive Director
- Sue Foden Ph.D., Non-Executive Director
How do I buy Evgen Pharma PLC stock?
Shares of Evgen Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Evgen Pharma PLC's stock price today?
One share of Evgen Pharma PLC stock can currently be purchased for approximately GBX 18.75.
MarketBeat Community Rating for Evgen Pharma PLC (LON EVG)MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Evgen Pharma PLC (LON:EVG) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | GBX 97 |
Consensus Price Target History for Evgen Pharma PLC (LON:EVG)
Analysts' Ratings History for Evgen Pharma PLC (LON:EVG)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 10/5/2017 | Beaufort Securities | Reiterated Rating | Speculative Buy | |  |
| 10/4/2017 | Northland Securities | Reiterated Rating | Buy | GBX 97 | |
| 1/4/2016 | Northland Capital Partners | Reiterated Rating | Buy | GBX 79 | |
(Data available from 10/17/2015 forward)
Earnings History for Evgen Pharma PLC (LON:EVG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Evgen Pharma PLC (LON:EVG)Current Year EPS Consensus Estimate: $4.90 EPS
Dividend History for Evgen Pharma PLC (LON:EVG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Evgen Pharma PLC (LON:EVG)Insider Trades by Quarter for Evgen Pharma PLC (LON:EVG)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/18/2016 | Clare,Barry | Insider | Buy | 40,000 | GBX 22 | £8,800 | |
(Data available from 1/1/2013 forward)
Headline Trends for Evgen Pharma PLC (LON:EVG)
Latest Headlines for Evgen Pharma PLC (LON:EVG)
| Source: |
|
Evgen Pharma PLC (EVG) Chart for Tuesday, October, 17, 2017
